Welcome to our dedicated page for Theratechnologies Common news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies Common stock.
Theratechnologies Inc. (symbol: THTX) is a biopharmaceutical company that markets prescription products across the United States, Europe, and Canada. Founded in 1993 and headquartered in Montreal, Canada, the company is dedicated to addressing the unmet medical needs of patients living with HIV and other serious health conditions.
Core Products:
- EGRIFTA and EGRIFTA SV: These products help reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their quality of life.
- Trogarzo: A vital injection treatment for multidrug-resistant HIV-1 infected patients, offering hope to those who have limited treatment options.
Pipeline Products:
- F8 Formulation: A promising treatment for HIV-associated lipodystrophy, currently in development.
- TH-1902: A potential breakthrough in the treatment of triple-negative breast cancer.
- TH-1904: Targeting ovarian cancer, another pipeline product with significant potential.
Theratechnologies generates significant revenue from its relationship with RxCrossroads, a major customer based in the United States. The company's strategic partnerships and innovative products showcase its commitment to improving patient outcomes in serious medical conditions. With a dedicated focus on research and development, Theratechnologies continues to make strides in the biopharmaceutical industry.
Rhea-AI Summary
Theratechnologies Inc. announces progression to next dose level in Phase 1 clinical trial for sudocetaxel zendusortide in advanced ovarian cancer patients, with positive safety outcomes and enrollment of first patient in second cohort.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. announces the resignation of Mr. Alain Trudeau from the Board of Directors and the Audit Committee. The Company plans to appoint a new independent director to ensure compliance with securities regulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
-
Rhea-AI Summary
Theratechnologies receives a refusal to file letter from the FDA for Trogarzo® IM administration, impacting their supplemental Biologics License Application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
Rhea-AI Summary
Theratechnologies Inc. reported a positive Adjusted EBITDA for Q4 2023, doubling from Q3 to $5 million, with a net loss of $2.8 million. The company achieved record quarterly revenue of $23.5 million and annual revenue of $81.8 million. Phase 1 trial for sudocetaxel zendusortide in ovarian cancer reached a milestone. Guidance for 2024 forecasts $87-90 million in revenue and $13-15 million EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. announces preclinical research results demonstrating the potential of sudocetaxel zendusortide in activating immune defense mechanisms and enhancing anti-PD-L1 immune-mediated tumor cell killing in triple-negative breast cancer. The publication highlights the superior tumor growth inhibition and immune cell infiltration compared to docetaxel in a murine tumor model, suggesting new avenues for combining immunotherapy with sudocetaxel zendusortide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. completes enrollment of the first six participants in Part 3 of Phase 1 clinical trial for TH1902 in advanced ovarian cancer patients, marking a significant milestone for the company's oncology development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
Rhea-AI Summary
Theratechnologies Inc. will report financial results and provide a business update for its fiscal 2023. They will also address the Complete Response Letter issued by the U.S. FDA for the F8 formulation of tesamorelin. The call will be hosted by Mr. Paul Lévesque, President and CEO, and other members of the management team. Participants are encouraged to join the call at least ten minutes in advance to secure access. Webcast and replay information is available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. received a Complete Response Letter (CRL) from the FDA for the F8 formulation of tesamorelin, related to chemistry, manufacturing, and controls (CMC) and immunogenicity risk. The CRL does not affect the commercial availability of EGRIFTA SV®, the F4 formulation of tesamorelin, currently the only approved medication in the U.S. for reducing excess abdominal fat in adults with HIV and lipodystrophy. The company plans to address the FDA's concerns and pursue approval for the newer formulation of tesamorelin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.95%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. received correspondence from the FDA regarding the sBLA for the F8 formulation of tesamorelin. The FDA is continuing its review of the application past the PDUFA goal date of January 22, 2024. Further information will be provided in due course.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
News
Rhea-AI Summary
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) files supplemental Biologics License Application for intramuscular method of administration for Trogarzo® (ibalizumab-uiyk) maintenance dose for treatment of heavily treatment-experienced adults with HIV, following recent FDA approval of IV push loading dose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.32%
Tags
FAQ
What is the current stock price of Theratechnologies Common (THTX)?
The current stock price of Theratechnologies Common (THTX) is $1.2 as of November 22, 2024.
What is the market cap of Theratechnologies Common (THTX)?
The market cap of Theratechnologies Common (THTX) is approximately 55.2M.
What does Theratechnologies Inc. specialize in?
Theratechnologies Inc. specializes in biopharmaceutical solutions for HIV and serious medical conditions like cancer.
Where are Theratechnologies' products marketed?
Theratechnologies markets its products in the United States, Europe, and Canada.
What are the main products offered by Theratechnologies?
The main products include EGRIFTA and EGRIFTA SV for HIV-related lipodystrophy and Trogarzo for multidrug-resistant HIV-1.
What are Theratechnologies' pipeline products?
Pipeline products include the F8 formulation for HIV-associated lipodystrophy, TH-1902 for triple-negative breast cancer, and TH-1904 for ovarian cancer.
When was Theratechnologies Inc. founded?
Theratechnologies Inc. was founded in 1993.
Where is Theratechnologies Inc. headquartered?
Theratechnologies Inc. is headquartered in Montreal, Canada.
Who is a major customer of Theratechnologies?
RxCrossroads, based in the United States, is a major customer of Theratechnologies.
What is the significance of Trogarzo?
Trogarzo is an important treatment for patients with multidrug-resistant HIV-1, providing a crucial option for those with limited alternatives.
How does EGRIFTA benefit HIV patients?
EGRIFTA helps reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their health and quality of life.
What is Theratechnologies' approach to innovation?
Theratechnologies focuses on research and development to create innovative treatments for serious medical conditions and improve patient outcomes.
Theratechnologies Inc. Common